GlassScriptPhysician profile
Kenneth Bruce Blankstein
NPI 1184612566
$11,976.60
in general payments reported to CMS, 2019-2025
80 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $2,045 · 2021: $2,725 · 2022: $914 · 2023: $1,795 · 2024: $2,265 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,915 · Long Term Medical Supply Or Device Loan: $1,196 · Entertainment: $247 · Education: $45.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,914.62 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Entertainment | $247.00 |
| Education | $45.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,997.83 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,647.19 | 2019-2025 | |
| Taiho Oncology, INC. | $1,388.42 | 2020-2025 | |
| Janssen Biotech, INC. | $575.14 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $563.26 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $370.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $358.52 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $266.89 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Asd Specialty Healthcare, LLC | $247.00 | 2023 | |
| Stemline Therapeutics INC. | $213.20 | 2023-2025 | Orserdu |
| Genzyme Corporation | $210.47 | 2020-2025 | |
| Celgene Corporation | $203.34 | 2019-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $203.27 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Astellas Pharma US INC | $201.51 | 2019-2024 | Xtandi, Padcev, Vyloy |
| Glaxosmithkline, LLC. | $194.71 | 2023-2025 | Zejula, Jemperli, Ojjaara |
Show all 79 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Blankstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.